

Wet Macular Degeneration Market Growing Rapidly with Market Share, Latest Trend and Future scope with Top Key Players

The increasing prevalence of wet macular degeneration and the rise in demand for eylea is increasing the growth of the wet macular degeneration market.

HYDERABAD, TELANGANA, INDIA, January 19, 2023 /EINPresswire.com/ -- The [Wet Macular Degeneration Market](#) size is forecast to reach \$8.71 billion by 2025, growing at a CAGR of 8.11% during the forecast period 2020-2025. The increasing prevalence of eye disorders and the increasing geriatric population are the major factors

driving the growth of the market. A growing number of drug approvals is set to further enhance the overall market demand for wet macular degeneration during the forecast period 2020-2025. The increasing prevalence of wet macular degeneration and the rise in demand for eylea is increasing the growth of the wet macular degeneration market. Eylea is a prescription medicine given by injection into the eye. One should not use EYLEA if they have an infection in or around the eye, eye pain or redness or known allergies to any of the ingredients in EYLEA, including aflibercept. EYLEA is an anti-vascular endothelial growth factor (anti-VEGF) treatment that is given by injection into the eye and works by blocking VEGF. EYLEA blocks VEGF by trapping it between its molecular arms. Eylea is used in the treatment of wet macular degeneration. Thus, increasing the demand for the wet macular degeneration market.

Click here to browse the complete report summary:

<https://www.industryarc.com/Report/16865/wet-macular-degeneration-market.html>

Key Takeaways

1. North America dominated the Wet Macular Degeneration Market owing to the increasing geriatric population and a growing number of drug approvals by the key players present in this region. The Wet Macular Degeneration Market scope for different regions will be provided in the



Market Research Reports, Business Consulting
Services & Analytics

final report.

2. The increasing prevalence of wet macular degeneration and the rise in demand for Eylea is likely to aid in the market growth of wet macular degeneration.
3. Detailed analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Wet Macular Degeneration Market report.
4. The high cost of on-label drugs and an increase in off-label drugs are set to create hurdles for the Wet Macular Degeneration Market.

Interested in knowing more relevant information? Click here:

<https://www.industryarc.com/pdfdownload.php?id=16865>

Segment Analysis

1. The Eylea segment held the largest share in the Wet Macular Degeneration Market in 2019 and is estimated to grow at a CAGR of 6.39% during the forecast period 2020-2025. This is owing to the increasing prevalence of wet macular degeneration and the rise in demand for Eylea. In people with certain types of eye disorders, new blood vessels grow under the retina where they leak blood and fluid. Lucentis is used to treat the wet form of age-related macular degeneration. Lucentis is also used to treat swelling in the retina caused by diabetes or by a blockage in the blood vessels. For wet macular degeneration, it is given by injection into the eye and it is estimated that eylea is set to be the fastest-growing segment during the forecast period 2020-2025.
2. Intravitreal segment held the largest share in the Wet Macular Degeneration Market in 2019 owing as it is more effective owing to targeted drug delivery. An intravitreal injection is a shot of medicine into the eye. The inside of the eye is filled with a jelly-like fluid (vitreous). Most anti-VEGF injections are administered using intravitreal or intraocular injections. Intravenous is a therapy that delivers fluids directly into a vein. The intravenous route of administration can be used both for injections, using a syringe at higher pressures; as well as for infusions, typically using only the pressure supplied by gravity. Intravenous infusions are commonly referred to as drips.
3. North America dominated the wet macular degeneration market in 2019 with a share of more than 38.5%, followed by Asia Pacific owing to the increasing prevalence of wet macular degeneration as well as the rising number of drug approvals in the region. However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the growing geriatric population and prevalence of eye disorders along with the increase in pipeline drugs.

Competitive Landscape:

The top 5 players in the Wet Macular Degeneration Industry are -

1. Pfizer Inc.
2. F. Hoffmann-La Roche
3. Regeneron Pharmaceutical
4. Novartis Ag
5. Valeant Pharmaceutical International, Inc.

Click on the following link to buy the Wet Macular Degeneration Market Report

<https://www.industryarc.com/reports/request-quote?id=16865>

Why Choose IndustryARC?

IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website but also get personalized assistance on specific reports.

Contact Us:

Mr Venkat Reddy

IndustryARC

Email: venkat@industryarc.com, sales@industryarc.com

USA: (+1) 970-236-3677, (+1) 815-656-4596

IND: (+91) 40-485-49062

Venkat Reddy

IndustryARC

+1 614-588-8538

venkat@industryarc.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/612135401>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.